ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Richie TL, Saul A, 2002. Progress and challenges for malaria vaccines. Nature 415 :694–701.
-
2
Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 :97–106.
-
3
Fang XD, Kaslow DC, Adams JH, Miller LH, 1991. Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol 44 :125–132.
-
4
Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, Miller LH, 1993. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 26 :1182–1184.
-
5
Adams JH, Sim BKL, Dolan AS, Fang X, Kaslow DC, Miller LH, 1992. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci USA 89 :7085–7089.
-
6
Singh S, Pandey K, Chattopadhayay R, Yazdani SS, Lynn A, Bharadwaj A, Ranjan A, Chitnis C, 2001. Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy-binding protein. J Biol Chem 276 :17111–17116.
-
7
Xainli J, Cole-Tobian JL, Baisor M, Kastens W, Bockarie M, Yazdani SS, Chitnis CE, Adams JH, King CL, 2003. Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun 71 :2508–2515.
-
8
Michon P, Fraser T, Adams JH, 2000. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy Binding Protein. Infect Immun 68 :3164–3171.
-
9
Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE, 2004. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22 :3727–3737.
-
10
Fraser T, Michon P, Barnwell JW, Noe AR, AlYaman F, Kaslow DC, Adams JH, 1997. Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun 65 :2772–2777.
-
11
Xainli J, Baisor M, Kastens W, Bockarie M, Adams JH, King LC, 2002. Age-dependent cellular immune response to Plasmodium vivax Duffy binding protein in humans. J Immunol 169 :3200–3207.
-
12
Singh AP, Puri K, Chitnis CE, 2002. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol 31 :72–81.
-
13
Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S, 1979. Treatment of P. vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 73 :15–27.
-
14
Hans D, Pattnaik P, Bhattacharyya A, Shakri AR, Yasdani SS, Sharma M, Choe H, Farzan M, Chitnis C, 2005. Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol Microbiol 55 :1423–1434.
-
15
Golenda CF, Li J, Rosenberg R, 1997. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proc Natl Acad Sci USA 94 :6786–6791.
-
16
Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Sturchler D, 1999. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 adjuvant. Vaccine 17 :3145–3159.
-
17
Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP, 2003. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinea children. Vaccine 22 :30–41.
-
18
Aikawa M, Miller LH, Johnson J, Rabbege J, 1978. Erythrocyte entry by malaria parasites. A moving junction between erythrocyte and parasite. J Cell Biol 77 :72–82.
-
19
Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubowsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, 2004. Efficacy of the RTS, S/ASO2A vaccine against Plasmodium falciparum infection and disease in young African children: ramdomised controlled trial. Lancet 364 :1380–1383.
-
20
Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL, 2004. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 72 :949–957.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 5 | 5 | 5 |
| Full Text Views | 349 | 129 | 2 |
| PDF Downloads | 79 | 32 | 2 |
IMMUNOGENICITY AND PROTECTIVE EFFICACY OF RECOMBINANT VACCINE BASED ON THE RECEPTOR-BINDING DOMAIN OF THE PLASMODIUM VIVAX DUFFY BINDING PROTEIN IN AOTUS MONKEYS
Invasion of human erythrocytes by Plasmodium vivax requires interaction between Duffy binding protein (PvDBP) and the Duffy blood group antigen. The receptor-binding domain of PvDBP lies in a conserved N-terminal, cysteine-rich region, region II (PvRII). PvRII is a valuable malaria subunit vaccine candidate for asexual blood stages. We have evaluated in Aotus monkeys the immunogenicity and protective efficacy of recombinant PvRII formulated in Freund’s and Montanide ISA720 adjuvants. Specific antibody titers were determined by an enzyme-linked immunosorbent assay after each of three doses of 50 μg of protein administered by the subcutaneous route. Immunization with PvRII formulated in Freund’s adjuvant yielded higher antibody titers than immunization with the Montanide ISA720 formulation and offered partial protection. Although the Montanide ISA720 formulation was immunogenic, it did not provide any protection. Given the immunogenicity and partial protection observed, further studies are needed to optimize the PvRII vaccine formulation with adjuvants suitable for human use.